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Purpose/Objective: Knowledge about prostate cancer death 
(PCD) risks for an individual patient is essential to determine 
optimal treatment strategies. Long-term data from large 
prospective studies on this subject are scarce. The goal of 
our study was to reveal patterns and prognostic factors for 
PCD within established risk groups, using data from a clinical 
trial with long-term follow-up. 
Materials and Methods: Patients were treated (prostate, 
seminal vesicles) to 68 Gy or 78 Gy at daily fractions of 2 Gy 
in 1997-2002; 447 high-risk (HR) patients (≥T2c, PSA>20, 
and/or Gleason >7, according D’Amico), 90 low-risk (LR, T1-
T2b & Gleason ≤6 & iPSA ≤10) and 127 intermediate-risk (IR). 
Prognostic value of Gleason, iPSA, T stage, and baseline 
factors were evaluated, including pre-treatment patient-
reported GI and GU symptoms (questionnaire). Cox regression 
and Chi-square based risk classification trees were applied. 
For the latter the classified risk was PCD within 10y (yes/no). 
This classification method uses algorithms to create 
subgroups and cutoffs based on maximal distances between 
them. Cumulative incidences were calculated using Kaplan 
Meier analysis. 
Results: Median follow-up was 113 months. Prostate cancer-
specific survival (PCSS) at 10y was 97 % in the LR group (2 
cases of PCD), 93 % for IR (7 cases), and 74 % for HR (90 
cases, p<0.0001). Within the IR group, the classification tree 
identified 3 significantly different risk profiles for PCD < 10y: 
1) prostate volume ≤ 66 cc (0/62; 0.0 %), 2) volume > 66 cc & 
T1 (1/33; 3.0 %), and 3) volume > 66 & T2a/T2b (6/32; 18.8 
%). Cox regression confirmed that iPSA and Gleason had no 
prognostic value within the IR group. In the HR group, 
Gleason score <7 (n=171) was associated with a relatively low 
PCD risk (PCSS 91% at 10y, Figure 1A). For Gleason 7 (n=159) 
PCSS was 68% and for >7 (n=117) 57%. For HR - Gleason <7, 
the classification tree identified two risk profiles: 1) PSA ≤ 22 
(4/119; 3.4 %), and 2) PSA >22 (9/52; 17.3 %). For HR - 
Gleason ≥7 a risk of 10 % was identified for patients >74y 
(5/50). PCD risk for the remaining patients ≤74y and Gleason 
≥7 (n=226) appeared to be significantly associated with 
baseline reported GU symptoms of nocturia and straining, 
which was confirmed at Cox regression (nocturia p=0.003, 
straining p=0.005). PCSS at 10y in the latter group was 44 % 
in case of nocturia ≥4 and/or straining (n=65, 29 events) and 
67 % (n=161, 43 events) if these symptoms were absent 
(Figure 1B). 
 
 
 
Conclusions: Significant predictors for PCD were identified 
within the risk groups. Baseline GU symptoms were 
associated with aggressive and fatal disease for high-risk 
patients, suggesting that in these cases the symptoms are 
caused by tumor tissue. The HR subgroup with Gleason <7 & 
iPSA <≈20 (n=119, 27 % of HR) behaved as LR with a 10y PCSS 
of 96 %. IR patients with prostate volumes below 66 cc 
behaved as LR as well with a 10y PCSS of 100 %. Additional 
modeling and validation is needed for further interpretation 
of these findings. 
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Purpose/Objective: Assessing the main predictors of 
impotence 1 year after RT for prostate cancer (PCa).  
Materials and Methods: Within a multi-centric prospective 
study aimed to assess the predictors of GU toxicity and 
erectile disfunction after RT for PCa, 337 patients (pts) filled 
in the IIEF questionnaire before RT and were further 
requested to fill it in at the end of RT, and every 6 months up 
to 5 year from the end of RT. Based on IIEF questions 1-5 and 
15 (score range: 0-30, IIEFp), men were considered potent if 
IIEFp≥13: 155/337 pts were potent before RT and 90/155 did 
not receive any hormonal therapy (neo-adjuvant and/or 
adjuvant, HT-naive). At the time of analysis, 209/337 pts 
filled in the 1-year questionnaire and 53/209 were potent 
before RT and HT-naïve: moderate hypofractionation was 
used in 127/209 (2.35-2.7Gy/fr, 65-74.2Gy) while the 
remaining were treated with 1.8-2 Gy/fr (74-80Gy). Most pts 
were treated with IMRT (91%). Prospectively collected 
individual information (including age, BMI, comorbidities, use 
of drugs, previous surgery, smoke, HT, stage, PSA, GS, pelvic-
nodes RT) and D1% (as a surrogate of Dmax)/Dmean of the 
penile bulb (PB) contoured on the planning CT were available 
for this ad-interim analysis: D1%/Dmean were corrected into 
2Gy-equivalent doses using an alpha/beta =3 
(EQD2_1%/EQD2_mean). Predictors of 1-year potency were 
assessed through uni- and multi-variable backward logistic 
regression for the whole group and for the subgroup of 
potent, HT-naive pts.  
 
Results: In the whole group, potency at 1-year was predicted 
by a 2-variable model including pre-RT IIEFp (OR: 0.931, pvs 
EQD2_D1%. Best cut-off values based on ROC analysis showed 
that pre-RT IIEFp >22 and EQD2_D1% < or ≥ 74Gy respectively. 
The corresponding model taking the two dichotomized 
variables showed a higher AUC (0.78, 95%CI: 0.64-0.89): both 
variables were more robustly associated to impotency 
(EQD2_D1% ≥ 74Gy: OR: 8.7, p=0.004; IIEFp ≤ 22: OR: 
5.7,p=0.02).  
Conclusions: Despite the relatively small number of pts, our 
ad-interim results clearly showed that the dose to PB and the 
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pre-RT IIEFp robustly predict the 1-year risk of impotency 
after high-dose RT for PC in HT-naive, potent men. The steep 
relationship with EQD2_D1% suggests that 
avoiding/minimizing the overlap between PTV and PB (likely 
for most pts if using MRI) could dramatically improve potency 
preservation. 
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Purpose/Objective: Stereotactic ablative body radiotherapy 
(SABR) is an emerging non-invasive treatment modality for 
both small and large inoperable primary renal cell carcinoma 
(RCC)1. A dose/effect relationship of renal dysfunction post-
SBRT is yet to be established. We evaluate renal dysfunction 
post-treatment using nuclear medicine imaging and serum 
biochemistry.  
1 Siva S, Pham D, Gill S, et al: A systematic review of stereotactic radiotherapy ablation for 
primary renal cell carcinoma. BJU Int 110:E737-43, 2012 
Materials and Methods: As part of a prospective ethics board 
approved clinical trial, patients with primary RCC received 
single fraction 26Gy SBRT for tumours < 5cm, or 42Gy/3 
fractions of SBRT for tumours ≥ 5cm (biological equivalent 
dose [BED3Gy] of 251Gy and 238Gy, respectively). Prior to 
treatment, 14 days post treatment, and approximately 90 
days post-therapy, glomerular filtration rate (GFR) was 
measured by 51Cr-EDTA clearance and split renal perfusion 
was recorded by 99mTc-DMSA SPECT/CT. A subset of patients 
also underwent late nuclear medicine imaging at 1 year. The 
change in renal perfusion on SPECT/CT over time was 
evaluated across each 1Gy isodose bin. Toxicity was scored 
using Common Toxicity Criteria for Adverse Events (CTCAE) 
v4.0. 
Results: From July 2012 to August 2013, 21 patients were 
enrolled on trial, with a median follow-up of 12 months. In 9 
patients the referral was precipitated by the likely need for 
post-surgery dialysis. Patient characteristics are found in 
Table 1. No patient sustained grade 3+ toxicities, 5/21 
patients (24%) had grade 2 toxicities (fatigue, flank pain, 
haematuria), and 5/21 (24%) patients were asymptomatic 
from treatment. The mean (+/- SD) GFR at baseline was 52 
+/- 24 mls/min and was 55 +/- 32 mls/min at ~90 days 
(p=0.174). In a subset of 14 patients (7 single fraction and 7 
multi-fraction) undergoing late GFR scanning at a median of 
350 days post SBRT, there was a decrease in mean (+/- SD) 
GFR from baseline to 45 +/-14 mls/min (p=0.034). Local split 
functional assessed by SPECT imaging demonstrated linear 
correlation between functional loss and delivered dose 
(Figure 1). For single- and three-fraction cohorts, this was 
calculated at 3.2% and 2.3% percent loss from baseline per Gy 
delivered, respectively (Pearson r2 range 0.499-0.953, all p-
values < 0.001). When normalising both groups by BED, this 
equates to 2.9% per 10Gy BED3Gy (r2= 0.876, p < 0.001). The 
split differential % loss in function in the treated kidney was -
27% (+/- 34%), and split differential % compensatory gain in 
the unaffected kidney was +14% (+/- 28%). The mean serum 
creatinine was worse at 1-year post SBRT at 162 umol/L 
compared to baseline of 131 umol/L (p=0.02). No patient 
required dialysis. 
 
